Abstract
Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) is an analog of deoxycytidine. It is transformed to the active triphosphate(dFdCTP) after intracellular phosphorylation. Gemcitabine monophosphate is inserted into the DNA and inhibits DNA elongation as a false nucleotide. In contrast to other antimetabolites, an additional, altered nucleotide is inserted behind dFdC inhibiting repair mechanisms (masked chain termination). By this, repair enzymes (exonucleases) of the DNA are inhibited and repair mechanisms are prevented. This factor, as well as enzymic inhibition of gemcitabine diphosphate, lead to high intracellular concentrations of gemcitabine and enforce the cytostatic effect. Gemcitabine is mostly inserted into DNA but partly also into RNA. Competition at the receptor with the nucleoside deoxycytidine phosphate (dCTP) leads to a competitive inhibition of DNA polymerases.1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
